Analysts Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $106.85

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $104.5385.

Several equities analysts have recently weighed in on SLNO shares. TD Cowen lowered their price target on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Oppenheimer reduced their price objective on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a research report on Wednesday. Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research report on Tuesday, January 13th. Finally, HC Wainwright cut their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th.

Soleno Therapeutics Stock Down 2.4%

SLNO opened at $32.80 on Monday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average price of $40.02 and a 200-day moving average price of $50.32. Soleno Therapeutics has a twelve month low of $32.15 and a twelve month high of $90.32. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of 142.61 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. Equities research analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current year.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Oppenheimer lowered its price target on SLNO from $110 to $80 but kept an “Outperform” rating, signaling the analyst still sees significant upside versus current levels while dialing back assumptions. Oppenheimer price target cut
• Negative Sentiment: Multiple law firms have filed or announced investor alerts about a securities class action alleging material misstatements/omissions related to Soleno’s Phase 3 clinical program for DCCR (VYKAT™ XR) and reported launch disruptions. Firms publicly soliciting clients and lead‑plaintiff applicants include Kessler Topaz, Hagens Berman, Levi & Korsinsky, Frank R. Cruz, Robbins Geller, Faruqi & Faruqi, Rosen, Kahn Swick & Foti, Glancy Prongay, Schall, Bernstein Liebhard and others. These filings raise the prospect of litigation costs, potential damages, management distraction and reputational harm that can pressure the stock; the lead‑plaintiff deadline cited in many notices is May 5, 2026. Kessler Topaz investor alert

Institutional Trading of Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after acquiring an additional 1,691,057 shares during the period. Braidwell LP bought a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at $86,662,000. Janus Henderson Group PLC grew its position in shares of Soleno Therapeutics by 18.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after acquiring an additional 1,122,015 shares during the period. Invesco Ltd. increased its stake in shares of Soleno Therapeutics by 132.3% in the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares in the last quarter. Finally, Commodore Capital LP increased its stake in shares of Soleno Therapeutics by 121.3% in the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.